Details of the Drug

General Information of Drug (ID: DMDZF6C)

Drug Name

SAR445136

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Cell therapy

Cross-matching ID

References

1	ClinicalTrials.gov (NCT05145062) An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant. U.S.National Institutes of Health.